It has recently been shown that increased metastatic activity as a side effect of tamoxifen treatment of ERα-positive breast cancer is due to the fact that decreased ERα expression may promote amoeboid migration breast cancer cells because ERα suppresses amoeboid cell movement by upregulating vinculin (Gao et al., 2017). Here, VCL is linked to breast carcinoma.